Actively Recruiting
Prospective Cohort Study on the Determinants of Venous THromboembolic Recurrence
Led by University Hospital, Brest · Updated on 2025-09-12
3400
Participants Needed
4
Research Sites
1557 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The main objective of the BREIZH-Cohorte study is to determine the incidence of recurrent short, medium and long-term thromboembolic venous disease as well as risk factors for recurrence in two specific populations: patients under 50 years of age, men and women (5 year recurrence), as well as cancer patients (all ages) (1 year recurrence).
CONDITIONS
Official Title
Prospective Cohort Study on the Determinants of Venous THromboembolic Recurrence
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Subject aged 18 or over, or a minor with consent from parents and the minor, presenting with thromboembolic venous disease
- Age 50 years or younger, or any age if active cancer is present
- Affiliated to social security
- Willing to participate in the study
You will not qualify if you...
- Unable to communicate due to comprehension difficulties
- Refusal to participate in the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
CHRU Brest
Brest, France, 29200
Actively Recruiting
2
HIA Clermont Tonnerre Brest
Brest, France, 29200
Actively Recruiting
3
CH Morlaix
Morlaix, France, 29672
Actively Recruiting
4
CH de Cornouaille
Quimper, France, 29107
Actively Recruiting
Research Team
F
Francis COUTURAUD, MD, PHD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here